MediciNova, Inc.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, MediciNova is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $1.41, 59.1% below its 52-week high and below its 200-day average, which is rising.

$1.41

+3.02% today

$69.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is MNOV early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 32w

S2 22w

S4 32w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 5w → S3 2w → S4 32w → S1 4w → S4 5w → S1 1w → S4 5w → S1 2w → S2 22w → S3 6w → S4 32w → S1 4w → S2 17w → S3 7w → S4 13w → S1 3w → S2 5w current

Total tracked: 166 weeks across 17 stage runs.

MNOV among Biotechnology148th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…148	MNOVMediciNova, Inc.	Stage 2 · wk 6	66	−49.6%

vs 52W High

-59.1%

$1.18 lo$3.45 hi

59.1% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-6.9%

200 DMA: $1.52 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.07x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-49.6%

+6.8%

+2.9%

YTD

+6.0%

+15.6%

Scan Membership

Breakout Watch

Latest: 2024-09-20

8 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 6 · Vol 0.07x

2026-10-21S2

Wk 6 · Vol 0.07x

2026-10-20S2

Wk 5 · Vol 0.09x

2026-10-19S2

Wk 5 · Vol 0.35x

2026-10-16S2

Wk 5 · Vol 0.20x

2026-10-15S2

Wk 5 · Vol 0.15x

2026-10-14S2

Wk 5 · Vol 0.24x

2026-10-13S2

Wk 4 · Vol 0.09x

2026-10-12S2

Wk 4 · Vol 0.32x

2026-10-09S2

Wk 4 · Vol 0.17x

2026-10-08S2

Wk 4 · Vol 0.27x

2026-10-07S2

Wk 4 · Vol 0.20x

Moving averages & range

50 DMA

$1.78

200 DMA

$1.52

52W High

$3.45

52W Low

$1.18

5D Low

$1.36

Resistance levels (recent highs)

20d High

$2.58

60d High

$3.45

120d High

$3.45

250d High

$3.45

Next resistance

+83.0%

to 20d High

ROE

-25.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.9

MediciNova: quick answers

What stage is MediciNova in?

As of Oct 22, 2026, MediciNova (MNOV) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is MediciNova in an uptrend?

Yes. MediciNova is in a Stage 2 uptrend. It trades 6.9% below its 200-day average, which is rising.

How far is MediciNova from its 52-week high?

MediciNova closed at $1.41 on Oct 22, 2026, 59.1% below its 52-week high of $3.45. Its 52-week low is $1.18.

How has MediciNova performed over the past year?

As of Oct 22, 2026, MediciNova is up 15.6% over the past year and up 6.0% so far in 2026.

Which sector and industry is MediciNova in?

MediciNova is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.